Pain management · 2025
Patient-centered outcomes in the acute treatment of migraine: a prospective, real-world, longitudinal survey study (UNIVERSE II) comparing migraine patients who switch from a prior triptan to another triptan or ubrogepant.
СтатьяСравнительное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Lipton Richard B, Bodhani Amit, Gao Xingyu, Duan Molly, Wilson Lauren, Cadiou Francois, Gandhi Pranav, Jariwala-Parikh Krutika
Аннотация
OBJECTIVE: Evaluate the real-world experience of ubrogepant versus triptans for the acute treatment of migraine among participants switching from an oral triptan.
METHODS: UNIVERSE II was a prospective, longitudinal, survey-based, real-world study conducted in adult Migraine Buddy application users who self-reported a switch from an oral triptan to another oral triptan or ubrogepant. The 4-week study assessed treatment satisfaction, preference for the new treatment or previous triptan, and patient experience with new treatment against previous triptan.
RESULTS: Of 694 participants, 211 were included after screening and accounting for dropouts (triptan, n = 100; ubrogepant, n = 111). At Day 30, significantly greater proportion of the ubrogepant cohort reported satisfaction with treating pain associated with migraine (69.4% vs 42.0%; adjusted odds ratio [OR] = 3.22; [95% confidence interval [CI], 1.80-5.88]; p < 0.001) and alleviating their most bothersome symptom (69.4% vs 42.0%; adjusted OR = 3.10; [95% CI, 1.75-5.60]; p < 0.001) compared with those who switched triptans. The ubrogepant cohort was more likely to prefer their new treatment to their prior triptan (75.7% vs 63.0%; adjusted OR = 1.93; [95% CI, 1.05-3.59]; p = 0.035) and reported better meaningful relief at 2 hours compared to prior triptan (75.7% vs 59.0%; adjusted OR = 2.30; [95% CI, 1.26-4.27]; p = 0.007).
CONCLUSION: This real-world study demonstrated people with migraine who switched from a triptan to ubrogepant reported better outcomes than those who switched to a different triptan.
METHODS: UNIVERSE II was a prospective, longitudinal, survey-based, real-world study conducted in adult Migraine Buddy application users who self-reported a switch from an oral triptan to another oral triptan or ubrogepant. The 4-week study assessed treatment satisfaction, preference for the new treatment or previous triptan, and patient experience with new treatment against previous triptan.
RESULTS: Of 694 participants, 211 were included after screening and accounting for dropouts (triptan, n = 100; ubrogepant, n = 111). At Day 30, significantly greater proportion of the ubrogepant cohort reported satisfaction with treating pain associated with migraine (69.4% vs 42.0%; adjusted odds ratio [OR] = 3.22; [95% confidence interval [CI], 1.80-5.88]; p < 0.001) and alleviating their most bothersome symptom (69.4% vs 42.0%; adjusted OR = 3.10; [95% CI, 1.75-5.60]; p < 0.001) compared with those who switched triptans. The ubrogepant cohort was more likely to prefer their new treatment to their prior triptan (75.7% vs 63.0%; adjusted OR = 1.93; [95% CI, 1.05-3.59]; p = 0.035) and reported better meaningful relief at 2 hours compared to prior triptan (75.7% vs 59.0%; adjusted OR = 2.30; [95% CI, 1.26-4.27]; p = 0.007).
CONCLUSION: This real-world study demonstrated people with migraine who switched from a triptan to ubrogepant reported better outcomes than those who switched to a different triptan.